Alnylam Pharmaceuticals, Inc.ALNYNASDAQ
Loading
SG&A Expense Growth Under PressureDecelerating
Percentile Rank50
3Y CAGR-0.1%
5Y CAGR+1.1%
Year-over-Year Change
Year-over-year SG&A expense growth
3Y CAGR
-0.1%/yr
vs -28.4%/yr prior
5Y CAGR
+1.1%/yr
Consistent
Acceleration
+28.3pp
Accelerating
Percentile
P50
Within normal range
vs 5Y Ago
1.1x
Modest growth
Streak
2 yr
Consecutive growthDecelerating
| Period | Value |
|---|---|
| 2025 | 24.11% |
| 2024 | 22.61% |
| 2023 | 3.24% |
| 2022 | 24.17% |
| 2021 | 5.48% |
| 2020 | 22.84% |
| 2019 | 25.28% |
| 2018 | 91.79% |
| 2017 | 123.12% |
| 2016 | 47.42% |